Rationale and design of the DIPAK 1 study: A randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease

American Journal of Kidney Diseases

Volumn 63, Issue 3, 2014, Pages 446-455

  Meijer, Esther ^a   Drenth, Joost P H ^b   D'Agnolo, Hedwig ^b   Casteleijn, Niek F ^a   De Fijter, Johan W ^c   Gevers, Tom J ^b   Kappert, Peter ^a   Peters, Dorien J M ^c   Salih, Mahdi ^d   Soonawala, Darius ^c   Spithoven, Edwin M ^a   Torres, Vicente E ^e   Visser, Folkert W ^a   Wetzels, Jack F M ^b   Zietse, Robert ^d   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MAYO CLINIC   (United States)

Author keywords

cyst progression; disease trajectory; glomerular filtration rate (GFR); kidney volume; Polycystic kidney disease (PKD); quality of life (QoL); renal disease; somatostatin analog

Indexed keywords

CYST PROGRESSION; DISEASE TRAJECTORY; GLOMERULAR FILTRATION RATE (GFR); KIDNEY VOLUME; POLYCYSTIC KIDNEY DISEASE (PKD); QUALITY OF LIFE (QOL); RENAL DISEASE; SOMATOSTATIN ANALOG;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; QUALITY OF LIFE; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894470938     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.011     Document Type: Article

References (58)

1. J.J. Grantham Clinical practice. Autosomal dominant polycystic kidney disease N Engl J Med 359 14 2008 1477 1485
2. N. Hateboer, M.A. v Dijk, and N. Bogdanova et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group Lancet 353 9147 1999 103 107
3. B.Y. Reed, K. McFann, and M.R. Bekheirnia et al. Variation in age at ESRD in autosomal dominant polycystic kidney disease Am J Kidney Dis 51 2 2008 173 183
4. K.T. Bae, F. Zhu, and A.B. Chapman et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Cohort Clin J Am Soc Nephrol 1 1 2006 64 69
5. T.J. Gevers, and J.P. Drenth Diagnosis and management of polycystic liver disease Nat Rev Gastroenterol Hepatol 10 2 2013 101 108
6. V.E. Torres Treatment strategies and clinical trial design in ADPKD Adv Chronic Kidney Dis 17 2 2010 190 204
7. R.W. Schrier Randomized intervention studies in human polycystic kidney and liver disease J Am Soc Nephrol 21 6 2010 891 893
8. P. Ruggenenti, A. Remuzzi, and P. Ondei et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int 68 1 2005 206 216
9. V.E. Torres, E. Meijer, and K.T. Bae et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study Am J Kidney Dis 57 5 2011 692 699
10. J.M. Shillingford, K.B. Piontek, G.G. Germino, and T. Weimbs Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1 J Am Soc Nephrol 21 3 2010 489 497
11. J.M. Shillingford, N.S. Murcia, and C.H. Larson et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease Proc Natl Acad Sci U S A 103 14 2006 5466 5471
12. Y. Tao, J. Kim, R.W. Schrier, and C.L. Edelstein Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease J Am Soc Nephrol 16 1 2005 46 51
13. G. Walz, K. Budde, and M. Mannaa et al. Everolimus in patients with autosomal dominant polycystic kidney disease N Engl J Med 363 9 2010 830 840
14. A.L. Serra, D. Poster, and A.D. Kistler et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease N Engl J Med 363 9 2010 820 829
15. E. Higashihara, V.E. Torres, and A.B. Chapman et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience Clin J Am Soc Nephrol 6 10 2011 2499 2507
16. V.E. Torres, A.B. Chapman, and O. Devuyst et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease N Engl J Med 367 25 2012 2407 2418
17. V.E. Torres, and P.C. Harris Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases Nat Clin Pract Nephrol 2 1 2006 40 55 quiz 55
18. L. van Keimpema, F. Nevens, and R. Vanslembrouck et al. Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial Gastroenterology 137 5 2009 1661 1668 e1-e2
19. M.C. Hogan, T.V. Masyuk, and L.J. Page et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 6 2010 1052 1061
20. A. Caroli, L. Antiga, and M. Cafaro et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 5 2010 783 789
21. M.C. Hogan, T.V. Masyuk, and L. Page et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 9 2012 3532 3539
22. A. Caroli, N. Perico, and A. Perna et al. Effect of long-acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial Lancet 382 9903 2013 1485 1495
23. Y. Pei, J. Obaji, and A. Dupuis et al. Unified criteria for ultrasonographic diagnosis of ADPKD J Am Soc Nephrol 20 1 2009 205 212
24. A.S. Levey, T. Greene, J. Kusek, and G. Beck A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract] J Am Soc Nephrol 11 2000 155A
25. M. Barbanoj, R. Antonijoan, and A. Morte et al. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency Clin Pharmacol Ther 66 5 1999 485 491
26. R.W. Schrier, K.K. McFann, and A.M. Johnson Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease Kidney Int 63 2 2003 678 685
27. R.W. Schrier Optimal care of autosomal dominant polycystic kidney disease patients Nephrology (Carlton) 11 2 2006 124 130
28. R. Sherstha, C. McKinley, and P. Russ et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease Hepatology 26 5 1997 1282 1286
29. Y. Pirson Extrarenal manifestations of autosomal dominant polycystic kidney disease Adv Chronic Kidney Dis 17 2 2010 173 180
30. H.J. Bovenschen, M.J. Janssen, M.G. van Oijen, R.J. Laheij, L.G. van Rossum, and J.B. Jansen Evaluation of a gastrointestinal symptoms questionnaire Dig Dis Sci 51 9 2006 1509 1515
31. R.E. Gislefoss, T.K. Grimsrud, and L. Morkrid Stability of selected serum proteins after long-term storage in the Janus serum bank Clin Chem Lab Med 47 5 2009 596 603
32. E.M. Spithoven, S.J. Bakker, J.E. Kootstra-Ros, P.E. de Jong, and R.T. Gansevoort DIPAK Consortium Investigators. Stability of creatinine and cystatin C in whole blood Clin Biochem 46 15 2013 1611 1614
33. S. Klahr, J.A. Breyer, and G.J. Beck et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group J Am Soc Nephrol 5 12 1995 2037 2047
34. D.J. Peters, L. Spruit, and J.J. Saris et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease Nat Genet 5 4 1993 359 362
35. T. Mochizuki, G. Wu, and T. Hayashi et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein Science 272 5266 1996 1339 1342
36. Anonymous Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium Cell 81 2 1995 289 298
37. P.C. Harris, and V.E. Torres Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy Curr Opin Nephrol Hypertens 15 4 2006 456 463
38. F.A. Belibi, G. Reif, and D.P. Wallace et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells Kidney Int 66 3 2004 964 973
39. S.W. Lamberts, A.J. van der Lely, W.W. de Herder, and L.J. Hofland Octreotide N Engl J Med 334 4 1996 246 254
40. V.E. Torres, and P.C. Harris Autosomal dominant polycystic kidney disease: the last 3 years Kidney Int 76 2 2009 149 168
41. S. Lesche, D. Lehmann, F. Nagel, H.A. Schmid, and S. Schulz Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro J Clin Endocrinol Metab 94 2 2009 654 661
42. J.D. Carmichael Lanreotide depot deep subcutaneous injection: A new method of delivery and its associated benefits Patient Prefer Adherence 6 2012 73 82
43. S. Reichlin Somatostatin N Engl J Med 309 24 1983 1495 1501
44. S. Bhandari, N. Watson, and E. Long et al. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney J Histochem Cytochem 56 8 2008 733 743
45. T.V. Masyuk, A.I. Masyuk, V.E. Torres, P.C. Harris, and N.F. Larusso Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate Gastroenterology 132 3 2007 1104 1116
46. T.V. Masyuk, B.N. Radtke, and A.J. Stroope et al. Pasireotide is more effective than octreotide in reducing hepato-renal cystogenesis in rodents with polycystic kidney and liver diseases Hepatology 58 1 2012 409 421
47. M. Chrispijn, F. Nevens, and T.J. Gevers et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2 2012 266 274
48. M.C. Hogan, T.V. Masyuk, and L. Page et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 9 2012 3532 3539
49. T.J. Gevers, M. Chrispijn, J.F. Wetzels, and J.P. Drenth Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease BMC Nephrol 13 2012 17-2369-13-17
50. Hogan M. Pasireotide LAR in severe polycystic liver disease. Study number: NCT 01670110. http://www.clinicaltrials.gov/ct2/show/NCT01670110. Accessed August 17, 2012.
51. Mario Negri Institute for Pharmacological Research. Somatostatin in patients with autosomal dominant polycystic kidney disease and moderate to severe renal insufficiency (ALADIN 2). Study number: NCT 01377246. http://www.clinicaltrials.gov/ct2/show/NCT01377246. Accessed June 20, 2011.
52. M. Fleseriu Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: A literature review Pituitary 14 2 2011 184 193
53. T.J. Gevers, and J.P. Drenth Somatostatin analogues for treatment of polycystic liver disease Curr Opin Gastroenterol 27 3 2011 294 300
54. E. Meijer, W.E. Boertien, and F.L. Nauta et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis Am J Kidney Dis 56 5 2010 883 895
55. W.E. Boertien, E. Meijer, and J. Li et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort Am J Kidney Dis 61 3 2012 420 429
56. 2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug Nephrol Dial Transplant 26 8 2011 2445 2453
57. A. Schmidt, J. Pleiner, and G. Schaller et al. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release Kidney Int 61 5 2002 1788 1793
58. E.M. Spithoven, E. Meijer, and W.E. Boertien et al. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations Am J Kidney Dis 62 3 2013 531 540